Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents
Open Access
- 19 May 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5), e0155869
- https://doi.org/10.1371/journal.pone.0155869
Abstract
The face of hepatitis C virus (HCV) therapy is changing dramatically. Direct-acting antiviral agents (DAAs) specifically targeting HCV proteins have been developed and entered clinical practice in 2011. However, despite high sustained viral response (SVR) rates of more than 90%, a fraction of patients do not eliminate the virus and in these cases treatment failure has been associated with the selection of drug resistance mutations (RAMs). RAMs may be prevalent prior to the start of treatment, or can be selected under therapy, and furthermore they can persist after cessation of treatment. Additionally, certain DAAs have been approved only for distinct HCV genotypes and may even have subtype specificity. Thus, sequence analysis before start of therapy is instrumental for managing DAA-based treatment strategies. We have created the interpretation system geno2pheno[HCV] (g2p[HCV]) to analyse HCV sequence data with respect to viral subtype and to predict drug resistance. Extensive reviewing and weighting of literature related to HCV drug resistance was performed to create a comprehensive list of drug resistance rules for inhibitors of the HCV protease in non-structural protein 3 (NS3-protease: Boceprevir, Paritaprevir, Simeprevir, Asunaprevir, Grazoprevir and Telaprevir), the NS5A replicase factor (Daclatasvir, Ledipasvir, Elbasvir and Ombitasvir), and the NS5B RNA-dependent RNA polymerase (Dasabuvir and Sofosbuvir). Upon submission of up to eight sequences, g2p[HCV] aligns the input sequences, identifies the genomic region(s), predicts the HCV geno- and subtypes, and generates for each DAA a drug resistance prediction report. g2p[HCV] offers easy-to-use and fast subtype and resistance analysis of HCV sequences, is continuously updated and freely accessible under http://hcv.geno2pheno.org/index.php. The system was partially validated with respect to the NS3-protease inhibitors Boceprevir, Telaprevir and Simeprevir by using data generated with recombinant, phenotypic cell culture assays obtained from patients’ virus variants.Keywords
This publication has 77 references indexed in Scilit:
- Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor DaclatasvirAntimicrobial Agents and Chemotherapy, 2013
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)Antimicrobial Agents and Chemotherapy, 2012
- Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052Antimicrobial Agents and Chemotherapy, 2012
- In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335Antimicrobial Agents and Chemotherapy, 2012
- Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2010
- Evidence for separation of HCV subtype 1a into two distinct cladesJournal of Viral Hepatitis, 2010
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435Antimicrobial Agents and Chemotherapy, 2010
- GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796Antimicrobial Agents and Chemotherapy, 2009
- Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon SystemAntimicrobial Agents and Chemotherapy, 2008
- Phenotypic Characterization of Resistant Val 36 Variants of Hepatitis C Virus NS3-4A Serine ProteaseAntimicrobial Agents and Chemotherapy, 2008